Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 16 of 16 for “"pharmacokinetic modeling"”.
-
First-principle based pharmacokinetic modeling
… at the site of action is the hottest topic in pharmacokinetics (PK). In vitro-in vivo extrapolation (IVIVE) and physiological based pharmacokinetics (PBPK) models are two major PK prediction strategies. However, both IVIVE and PBPK models are considered as immature methodologies due to their …
-
The biodistribution of monoclonal antibodies and effector cells : pharmacokinetic modeling and its role in cancer diagnosis and therapy
Thesis (Sc. D.)--Massachusetts Institute of Technology, Dept. of Nuclear Engineering, 1996.
-
Translational high-dimesional drug interaction discovery and validation using health record databases and pharmacokinetics models
… Finally, combining epidemiological studies and pharmacokinetic modeling with fm database, we detected and evaluated high-dimensional drug-drug interactions among thirty high frequency drugs. Multi-drug combinations that increased risk of myopathy were identified in the FAERS and EMR databases by …
-
Learning and model-based approaches to improved patient monitoring, assessment and treatment in capnography and procedural sedation
… with those of relevant clinical events. Through pharmacokinetic modeling, we continuously compute the estimated sedation agent plasma concentration of patients over the course of procedural sedation. In the analysis of 38 patients sedated with propofol and with regularly annotated Ramsay sedation …
-
Integrating Cell-level Kinetic Modeling into the Optimization of Cancer Therapeutics
… of the complex interplay between the drug's pharmacokinetics and its effect, is largely missing. For complex diseases such as cancer, systems biology models of therapeutically relevant cellular processes have proven valuable for identifying potent drug targets. So far, such information about …
-
Quantitative Positron Emission Tomography for Estimation of Absolute Myocardial Blood Flow
… quantitative images that can be analyzed with pharmacokinetic modeling to estimate regional blood flow to the myocardium. Estimating myocardial blood flow (MBF) could provide increased clinical value over MPI alone, particularly if it could be combined with the clinical protocol used in …
-
THE IMPACT OF CYP3A4*22 AND CYP3A5*3 ON DEXAMETHASONE AND 6-HYDROXY-DEXAMETHASONE PHARMACOKINETICS IN PHASE 1/2 CANCER PATIENTS
… to significantly affect CYP3A4/5 activities and pharmacokinetics of various CYP3A4/5 substrates. Dexamethasone is a widely used anti-inflammatory and immunosuppressive agent. In humans, dexamethasone is extensively metabolized by CYP3A4/5 to its major metabolite, 6-hydroxydexamethasone. …
-
Using an In Vitro-In Vivo Correlation for the ‘Bioequivalence by Design’ Development of an Immediate Release Carbamazepine Product
… absorption were calculated using classical pharmacokinetic modeling and then regressed against each product’s rate and extent of dissolution. Next, the classically defined clearance parameter was replaced using a physiologically based clearance model. This allowed routinely available …
-
Bevacizumab Effect on Topotecan Pharmacokinetics in a Murine Orthotopic Rhabdomyosarcoma Xenograft Model
… model. However, the effects of BEV on the pharmacokinetics of TPT and the antitumor activity of TPT have not been evaluated. This study aimed to investigate the effect of BEV on TPT systemic and tumoral pharmacokinetics and to determine how these changes affect the efficacy of TPT in the …
-
The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia
… 10/42 (23.8%) vs. control 6/48 (15.8%) p=0.414). Modeling reveals that the volume of distribution decreases as the serum creatinine concentration increseases, and the clearance decreases as the age increases CONCLUSIONS: Montelukast was not effective in reducing the moderate or severe BPD. …
-
STATIC AND DYNAMIC FORMS TO IDENTIFY DDI POTENTIAL AND SOURCES OF PHARMACOKINETIC VARIABILITY
… drug development, or MIDD, which employs dynamic modeling forms to determine important aspects to be addressed and included in a clinical trial. Pharmacokinetic modeling techniques can be mechanistic, semi-mechanistic, or non-mechanistic, and may aid in understanding how a drug is eliminated and …
-
Model-Guided Transdermal Formulation of 1α,25-Dihydroxyvitamin D3 for Improved Safety and Efficacy
… step for permeation. A physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model was further established to interpret the complex PK and PD interplay of 1,25(OH)2D3 and guide dosing selection. Based on the modeling and studies in vivo, we were able to determine that patches …
-
Characterisation of the pharmacological actions in humans of multiple vasoactive enzyme inhibitors with therapeutic potential in heart failure
… to intravenous infusion of big ET-1 (n=6) and pharmacokinetic modeling of orally dosed SLV 306 in healthy volunteers (n=29), the effect of 3 doses of SLV 306 and placebo given at four separate visits one week apart, on the pressor and neurohumoral response to intravenous infusion of big …
-
Hyperpolarized Carbon-13 Magnetic Resonance Measurements of Tissue Perfusion and Metabolism
<p>Hyperpolarized Magnetic Resonance Imaging (HP MRI) is an emerging modality that enables non-invasive interrogation of cells and tissues with unprecedented biochemical detail. This technology provides rapid imaging measurements of the activity of a small quantity of molecules with a strongly …